YiChang HEC ChangJiang Pharmaceutical Co., Ltd. provided earnings guidance for the year ended 31 December 2018. Based on the currently available unaudited consolidated management accounts of the Group and the preliminary assessment by the company's management, it is expected that the Group will record an increase in profit attributable to equity shareholders of the company of approximately 45% for the year ended 31 December 2018 as compared to that for the year ended 31 December 2017. The expected increase in profit attributable to equity shareholders of the Company is primarily attributed to the significant increase in the sales revenue of Kewei, the company's key product; the continuous strengthening of professional academic marketing promotion of the Company; and the increasing penetration of the products in medical institutions across the country.